Ramifications from the shutdown will be felt far beyond Washington, DC, halting many operations related to public health.

Since its approval, there have been no cases of Torsades de Pointes or unexplained sudden death among US patients treated with Caprelsa.

In HR+/HER- early breast cancer, the DFS benefits of adjuvant ribociclib plus NSAI treatment compared to NSAI alone persisted even a year after treatment completion.